Draft:Han-Oh Park
| Submission declined on 24 June 2025 by Cinder painter (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Han‑Oh Park | |
|---|---|
| Born | May 16, 1962 Inje County, Gangwon Province, South Korea |
| Nationality | South Korean |
| Alma mater | Seoul National University (B.S., Chemistry, 1984) KAIST (M.S., 1986; Ph.D., 1992, Chemistry) |
| Occupation(s) | Biochemist, entrepreneur, inventor |
| Known for | Founder and CEO of Bioneer Corporation |
Han‑Oh Park (born May 16, 1962) is a South Korean biochemist, entrepreneur, and inventor. He is the founder and CEO of Bioneer Corporation, regarded as South Korea's first biotechnology venture company.[1][2][3] Park has contributed to molecular diagnostics, microbiome research, RNA interference (RNAi) therapeutics, and cosmeceutical innovation.[1]
Education and early career
[edit]Park received a B.S. in Chemistry from Seoul National University in 1984 and earned an M.S. (1986) and Ph.D. (1992) in Chemistry from KAIST, with a focus on oligonucleotide synthesis and enzyme engineering.[1][2] Before founding Bioneer, he was a researcher at the Genetic Engineering Center (now Korea Research Institute of Bioscience and Biotechnology), working on genetic and diagnostic technologies.[1][2]
Career and achievements
[edit]Founding of Bioneer
[edit]In 1992, Park founded Bioneer Corporation as a spin-off from the Genetic Engineering Center (now Korea Research Institute of Bioscience and Biotechnology). He contributed to the commercialization and localization of genetic technologies in Korea—such as DNA synthesis, PCR, sequencing, siRNA, and miRNA—building domestic production capabilities.[1][2] Under his leadership, Bioneer expanded from life sciences into molecular diagnostics, siRNA therapeutics, microbiome research, and RNAi-based cosmetics.[1]
Molecular diagnostics and global health
[edit]Park led the development of solutions for molecular diagnostic testing, including nucleic acid extraction equipment and kits, real-time PCR instruments, and diagnostic assays. This enabled Bioneer to supply these products internationally. During the COVID-19 pandemic, Bioneer provided molecular diagnostic equipment and kits to over 90 countries, supporting the global response to infectious disease outbreaks.[3][1]
RNAi therapeutics development
[edit]Park invented SAMiRNA (Self-Assembled-Micelle inhibitory RNA), a nanoparticle platform designed to improve the delivery and stability of small interfering RNA (siRNA) therapeutics.[1] Using this technology, he oversaw the development of SRN-001, an siRNA-based drug candidate for idiopathic pulmonary fibrosis (IPF). Clinical development of SRN-001 was conducted by siRNAgen Therapeutics, a Bioneer subsidiary.[1] In 2024, a phase 1a clinical trial of SRN-001 was completed in Australia, with results indicating favorable safety and tolerability.[4][5]
Microbiome research
[edit]Park led the development of Lactobacillus gasseri BNR17, a probiotic strain originally isolated from human breast milk,[2][6][7] received the IR52 Jang Young-Shil Award in 2022 for its innovation.[8] BNR17 has been studied for its potential anti-obesity and metabolic benefits in peer-reviewed clinical trials and is protected by patents in multiple countries.[7][6] In 2017, AceBiome, a spin-off from Bioneer, was established to commercialize BNR17-based probiotic products.[6] BNR17 was also recognized as the Weight Management Ingredient of the Year at the 2018 NutraIngredients-USA Awards.[7]
Cosmeceuticals innovation
[edit]Park and his team developed CosmeRNA, an RNA-based anti-hair loss tonic that utilizes SAMiRNA technology.[1] In 2024, CosmeRNA was recognized in the Hair Products category at Cosmoprof Worldwide Bologna.[9][10] The efficacy of CosmeRNA was demonstrated in a human clinical trial, and the results were published in the journal Scientific Reports.[11]
Awards and recognition
[edit]Individual honors (Han-Oh Park)
- Gold Tower Order of Industrial Service Merit (2021) – awarded by the Republic of Korea for contributions to molecular diagnostics and export competitiveness.[2]
- POSCO TJ Park Prize for Technology (2023) – awarded for pioneering work in gene synthesis, amplification, and molecular diagnostics.[12]
BNR17 strain honors
- IR52 Jang Young-Shil Award (2022) – awarded for innovation in probiotic research.[8]
- NutraIngredients-USA Award (2018) – for weight management ingredient innovation.[7]
CosmeRNA product honors
- Cosmoprof Award (2024) – for cosmeceutical innovation.[9]
References
[edit]- ^ a b c d e f g h i j Han-Oh Park, President, Founder and CEO, Bioneer, South Korea. PharmaBoardroom. Retrieved 2025-06-24
- ^ a b c d e f 박한오 "국산 유전자 기술로 세계시장 뚫겠다". 머니투데이. Retrieved 2025-06-24
- ^ a b Bioneer to supply COVID-19 diagnostic kits to 100 countries. Korea IT Times. Retrieved 2025-06-24
- ^ NCT05984992: First-in-human Study of SRN‑001 in Healthy Participants. ClinicalTrials.gov. Retrieved 2025-06-24
- ^ The First-in-human Study of SRN-001 in Healthy Participants. MedPath. Retrieved 2025-06-24
- ^ a b c AceBiome, a subsidiary of Bioneer, announced on the 12th that it will... Maeil Business News Korea. Retrieved 2025-06-24
- ^ a b c d UAS Labs licenses BNR17 probiotic strain for weight management. NutraIngredients-USA. Retrieved 2025-06-24
- ^ a b 2022년 제12주 IR52 장영실상 수상작. IR52 공식 홈페이지. Retrieved 2025-06-24
- ^ a b The keys to success for Cosmoprof Awards winners. Cosmoprof. Retrieved 2025-06-24
- ^ 2024 Cosmoprof & Cosmopack Award Winners Are... Global Cosmetic Industry. Retrieved 2025-06-24
- ^ Yun SI, Lee SK, Goh EA, et al. (2022). "Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia." Scientific Reports. Retrieved 2025-06-24
- ^ POSCO TJ Park Prize 2023 Awardees. POSCO TJ Park Foundation. Retrieved 2025-06-24